Clinical Trial Details
— Status: Terminated
Administrative data
| NCT number |
NCT01751282 |
| Other study ID # |
RO1AR06034201A1 |
| Secondary ID |
|
| Status |
Terminated |
| Phase |
Phase 1
|
| First received |
December 13, 2012 |
| Last updated |
October 3, 2016 |
| Start date |
June 2010 |
| Est. completion date |
June 2015 |
Study information
| Verified date |
October 2016 |
| Source |
Roger Williams Medical Center |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
United States: Food and Drug Administration |
| Study type |
Interventional
|
Clinical Trial Summary
The purpose of this study is to determine the effectiveness of Autologous Bone
Marrow-Derived Mesenchymal Stem Cells (MSCs) in the treatment of non-healing wounds.
Description:
Sixty-six (66) subjects are planned to be enrolled into the trial. each subject's duration
of participation will be 24 weeks on therapy with a 4 week post-treatment visit. A run-in
phase of 2 weeks will be required prior to randomization/enrollment.
All subjects will receive appropriate and standard care for chronic wounds, including
dressings, bandages, and off-loading, if required. All subjects will receive either saline,
fibrin or MSCs in fibrin using an identical double-barreled syringe to keep the blind.
Therefore, subjects will then be randomized to one of three groups:
1. conventional standard therapy and control saline spray
2. conventional standard therapy and fibrin spray
3. conventional standard therapy and MSCs (autologous bone marrow-derived mesenchymal stem
cell)in fibrin spray
Screening Visit:
All inclusion and exclusion information will be reviewed to make sure that the subject is
eligible for entry into the study. The following procedures will be performed during this
two week period:
Biopsy - One (3 x 6 mm) biopsy will be taken from the edge of the wound for additional
diagnostic tests and for culturing of cells. The second (3-4 mm) biopsy will be taken from
the thigh for culturing of cells in the laboratory to assess the healing process. The thigh
biopsy will then be excised by taking about 3/4 inch long by 1/4 inch wide margin from
around it, and suturing it closed. The reason for this biopsy of the normal skin is so that
it can be used to compare the healing process to the chronic wound.
Blood Sampling - Blood will be drawn for laboratory testing to assess the overall
well-being, HIV, Hepatitis B & C and if the subject is a woman able to bear children, to
test for pregnancy.
Wound Measurements - Wound measurements will be taken to determine the size of the wound and
to assess for healing.
Randomization Visit:
If the wound has not reduced significantly in size, and the subject is still eligible for
the study; he/she will be assigned to a study treatment. The decision as to which treatment
he/she will receive will be determined by a process called randomization. Randomization is a
mathematical process used to guarantee that each participant in the study has an equal
chance of being assigned to any of the treatment options available.
The treatment groups that the subject may be assigned to are as follows:
Group #1 - Conventional Therapy and Control Saline Spray -The subject will receive
conventional therapy, wound measurements, photography and observations. At the Day 1
treatment visit a double-barrel syringe system will be used to deliver topically normal
saline to the wound. Up to 2 additional treatments will be applied at Weeks 3 & 6 (+ or - 2
or 3 days).
Group #2 -Conventional Therapy and Fibrin Spray - The subject will receive conventional
therapy, wound measurements, photography, and observations. At the Day 1 treatment visit a
double-barrel syringe system will be used to deliver topically fibrin alone to the wound. Up
to 2 additional treatments will be applied at Weeks 3 & 6 (+ or - 2 or 3 days).
Group #3 - Conventional Therapy and Autologous Bone Marrow-Derived Mesenchymal Stem Cells in
Fibrin Spray - The subject will receive conventional therapy, wound measurements,
photography and observations. At the Day 1 treatment visit a double-barrel syringe system
will be used to deliver topically autologous bone marrow-derived mesenchymal stem cells in
fibrin. Up to 2 additional treatments will be applied at Weeks 3 & 6 (+ or - 2 or 3 days) if
your wound is not healed.
Conventional Therapy - The subject will receive standard of care and accepted conventional
therapy, regardless of which of the three groups you will be randomized in. This standard of
care involves the use of dressings, bandages and protective ways to increase healing of your
wound.
Bone Marrow Aspirate - Depending on the treatment group that the subject is assigned to,
they will have either a bone marrow aspirate and/or sham (imitation) aspirate performed at
this visit.
Day 1 Treatment Visit:
All groups will receive the study treatment that was assigned at the randomization visit.
Wound measurements, clinical observations, wound dressings, adverse event reporting and
photography will be performed.
Weekly Follow-up Visits (Weeks 1-24):
All groups will return weekly for conventional therapy, wound measurements, clinical
observations, wound dressing changes, adverse event report, and photography. Two additional
study treatments will be given at Weeks 3 & 6 (+ or - 2 or 3 days) if the wound is not
healed.
Post-Treatment Follow-up Visit (Week 28):
All groups will return one month after 24 weeks of treatment for evaluation, wound
measurements, and photography.
Follow-up wound Biopsies:
Participants in all three study treatment groups will be asked to have an additional biopsy
of the wound edge at Week 6. This biopsy will only be taken if the wound has not healed.
